P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 256 500 KRW 1.18% Market Closed
Market Cap: 2.7T KRW
Have any thoughts about
PharmaResearch Co Ltd?
Write Note

PharmaResearch Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PharmaResearch Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
P
PharmaResearch Co Ltd
KOSDAQ:214450
Additional Paid In Capital
â‚©185B
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Additional Paid In Capital
â‚©14.8T
CAGR 3-Years
159%
CAGR 5-Years
79%
CAGR 10-Years
44%
SK Bioscience Co Ltd
KRX:302440
Additional Paid In Capital
â‚©1.2T
CAGR 3-Years
86%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Additional Paid In Capital
â‚©382.7B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
2%
H
Hugel Inc
KOSDAQ:145020
Additional Paid In Capital
â‚©394.5B
CAGR 3-Years
6%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Additional Paid In Capital
â‚©121.7B
CAGR 3-Years
-11%
CAGR 5-Years
10%
CAGR 10-Years
N/A
No Stocks Found

PharmaResearch Co Ltd
Glance View

Market Cap
2.7T KRW
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.

Intrinsic Value
278 629.45 KRW
Undervaluation 8%
Intrinsic Value
Price
P

See Also

What is PharmaResearch Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
185B KRW

Based on the financial report for Sep 30, 2024, PharmaResearch Co Ltd's Additional Paid In Capital amounts to 185B KRW.

What is PharmaResearch Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
8%

Over the last year, the Additional Paid In Capital growth was 8%. The average annual Additional Paid In Capital growth rates for PharmaResearch Co Ltd have been 10% over the past three years , 8% over the past five years .

Back to Top